Danish biotech firm Reapplix has issued shares for DKK 125 million and raised a convertible loan on DKK 23 million. The money will keep the company going until next year, but Reapplix is already looking for new funds. According to the CEO, the biotech firm keeps all opportunities open - including an IPO.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.